Robbins LLP is Investigating Whether Hims & Hers Health, Inc. (HIMS) Shared Customers' Protected Health Information With Advertising Platforms and Engaged in Other Deceptive Advertising Practices

Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.

Why Was Hims & Hers Sued?

According to the complaint, defendants failed to disclose to investors that:

(1) the Company shared consumers’ health information with third-party advertising platforms;

(2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;”

(3) the foregoing conduct subjected the Company to regulatory scrutiny;

(4) as a result, the Company was reasonably likely to incur fees and penalties; and

(5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did HIMS Stock Drop?

Plaintiff alleges that on July 29, 2026, during market hours, the Federal Trade Commission (“FTC”) announced it had filed a lawsuit against Hims “alleging that the telehealth provider shared consumers’ sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers’ privacy and deceives users about its billing and cancellation practices.”

According to the FTC’s complaint, Hims engages in other deceptive advertising practices, including failing to “clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is ‘right for them.’” The complaint further alleges that, contrary to its promises that the platform is “100% online, private, and secure,” Hims “shared sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc. (‘Snap’).”

On this news, shares of Hims declined $4.32, or 14.73%, to close at $25.00 on July 29, 2026.

Who May Be Eligible to Participate in the Hims & Hers Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Hims & Hers Health, Inc. securities during the applicable Class Period. If you purchased Hims & Hers Health, Inc. during this period and suffered investment losses, you may have rights under the federal securities laws. Submit a form for information.

Attorney Advertising. Past results do not guarantee a similar outcome.